Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib plus cytarabine versus imatinib alone in first chronic phase chronic myeloid leukemia
NL-OMON21778Phase 3Recruiting
- Sponsor
- HOVON
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib and cytarabine in chronic myelogenous leukemia (CML), sponsored by HOVON. Primary endpoint: Rate of major molecular response at 12 months. Started May 2006; status: recruiting.
02
Drugs
imatinibcytarabine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON21778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21778.